NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Chemomab Therapeutics Ltd. (CMMB) Stock Analysis

Chemomab Therapeutics Ltd. (CMMB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CMMB

$2.71

−$0.12 (−4.24%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CMMB with… →

CMMB Key Statistics

As of Sep 4, 2026
Trading
Open
$2.90
Previous Close
$2.83
Day's Range
2.71–2.94
52-Week Range
1.35–3.58
Volume
118.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.76
Valuation
Market Cap
$19.86M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.96
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$9.00M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
7.33M
1-Year Return
−11.15%
Dividend and dates
Avg Volume
148.89K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CMMB Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+64.24%
2025−77.21%
2024+254.90%
2023−84.06%
2022−53.62%
2021−75.07%
2020+23.57%
2019 (partial year)−87.04%

As of September 4, 2026.

CMMB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$9.00M—
2024$0.00−$13.95M—
2023$0.00−$24.22M—
2022$0.00−$27.65M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$9.57M−$9.00M—
2024$0.00—−$14.74M−$13.95M—
2023$0.00—−$25.46M−$24.22M—
2022$0.00—−$28.53M−$27.65M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CMMB Valuation vs Biotechnology Median

Median of 656 stocks
MetricCMMBBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Chemomab Therapeutics Ltd. (CMMB) at $19.86M. The company sits in the Healthcare sector, in the Biotechnology industry.

The 52-week range on file runs from $1.35 to $3.58. CMMB last closed at $2.71 on September 4, 2026. That is −$0.12 (−4.24%) against the previous close. The latest close sits 100.74% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $9.00M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.96.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the price has returned −11.15%. Across 5 years the annualized return works out at −45.92%. The reported beta is 0.76. Annualized volatility over the trailing 7 years is 131.71%.

Growth & Income

No dividend is on file for CMMB.

2026 is still running; the price is +64.24% year to date. Across the complete calendar years on file, 2024 returned +254.90% and 2023 returned −84.06%. Of the 6 complete calendar years on file, 2 finished higher.

Peer Comparison

Chemomab Therapeutics Ltd. (CMMB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Chemomab Therapeutics Ltd. CMMB $19.86M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Chemomab Therapeutics Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.

Visit website →